W. Thomas London, MD - Internal Medicine/Hepatology

Dr. London is a senior member in the Division of Population Science and director of the Liver Cancer Prevention Center at the Fox Chase Cancer Center. He is a senior member and adjunct scholar in the Center for Clinical Epidemiology and Biostatistics at the University of Pennsylvania School of Medicine. In addition, Dr. London is an associate editor for Cancer Epidemiology Biomarkers and Prevention and is widely published in peer-reviewed publications.

Dr. London received the Distinguished Scientist Award in 1998 from the Hepatitis B Foundation in Doylestown, PA, and the Distinguished Interdisciplinary Research Award in 1999 from the American Cancer Society, Southeast Region.

American Board of Internal Medicine

Hepatitis B

MD: Cornell University Medical College, New York, NY, 1957

Internship: Bellevue Hospital, 2nd Cornell Medical Division, New York, NY, 1957–1958

Residency: Medicine, Bellevue Hospital, 2nd Medical Division and Memorial Center (Combined Program), 1958–1960

Fellowship: Research Fellowship in Medicine (Endocrinology) Sloan-Kettering Institute, New York, NY, 1960–1962

Senior Member, Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA, 1990–present

Adjunct Professor of Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, 1999–present

Fox Chase Cancer Center, Philadelphia, PA

American Board of Internal Medicine

American College of Physicians

Endocrine Society

American Thyroid Association

American Association for Cancer Research

American Association for the Advancement of Science

American Medical Association

Philadelphia County Medical Society

John Morgan Society

Society for Epidemiologic Research

American Society for Virology

Philadelphia Epidemiology Society

American Society of Preventive Oncology

American Liver Foundation

Hepatitis B Foundation

1. Evans AA, O'Connell AP, Mason WS, M'boup S, Shen FM, London WT (In press). Heterogeneity of the pre-C/C region of hepatitis B virus (HBV) in chronic carriers from China and West Africa. In J Margolis et al., eds., Viral Hepatitis and Liver Disease. London: International Medical Press.
2. Gao LL, Chen G, Evans AA, Lin WY, O'Connell AP, Propert KJ, Williams S, Shen FM, London WT, and the Haimen City Cooperating Group (In press). Predicting hepatocellular carcinoma: A model developed from a 4-year prospective study of hepatitis B virus carriers. In H Margolis et al., eds., Viral Hepatitis and Liver Disease. London: International Medical Press.
3. McGlynn KA, Edmondson MN, Michielli RA, London WT, Lin WY, Shen FM, Buetow KH (In press). A phylogenetic analysis of loss of heterozygosity in hepatocellular carcinoma. Hepatology.
4. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT (In press). Eight-year follow-up of the 90,000-person Haimen City Cohort: I . Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiology Biomarkers and Prevention.
5. London WT (2002). Liver cancer: Etiology and prevention. In J Bertino et al., eds., Encyclopedia of Cancer, 2nd ed. San Diego: Academic Press.
6. Balsara BR, Pei J, De Rienzo A, Simon D, Tosolini A, Lu YY, Shen FM, Fan X, Lin WY, Buetow KH, London WT, Testa JR (2002). Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes, Chromosomes, and Cancer, 30: 245–253.
7. Steel LF, Mattu TS, Mehta A, Hebesteit H, Dwek R, Evans A, London WT, Block T (2001). A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Disease Markers, 17: 179–189.

Dr. London owns stock in Merck & Co.